FindTrial
Sign In

Efficacy and safety of teneligliptin in patients with type 2 diabetes who responded insufficiently to dipeptidyl peptidase-4 (DPP-4) inhibitors

Efficacy and safety of teneligliptin in patients with type 2 diabetes who responded insufficiently to dipeptidyl peptidase-4 (DPP-4) inhibitors - Efficacy and safety of teneligliptin in patients with type 2 diabetes who responded insufficiently to dipeptidyl peptidase-4 (DPP-4) inhibitors

Status
Active, not recruiting
Phases
Unknown
Study type
Interventional
Source
JPRN
Registry ID
JPRN-UMIN000014298
Enrollment
20
Registered
2014-06-18
Start date
2013-06-01
Completion date
Unknown
Last updated
2025-07-18

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

Type 2 diabetes

Interventions

teneligliptin

Sponsors

Naka Kinen Clinic
Lead Sponsor

Eligibility

Sex/Gender
All

Inclusion criteria

Inclusion criteria:

Exclusion criteria

Exclusion criteria: (1) Type-1 diabetes, diabetes due to a pancreatic disorder, or secondary diabetes due to conditions such as Cushing's syndrome and acromegaly (2) Application of contraindications contained in the package insert (3) Excessive alcohol consumption : mean daily intake of pure alcohol >=60g (4) Pregnant women, women suspected of being pregnant, or lactating women (5) Participation in the study is judged by the investigator or sub-investigator as inappropriate for any other reason

Design outcomes

Primary

MeasureTime frame
Change in Glycosylated hemoglobin(HbA1c) levels over 12 weeks,Change in DPP-4 activity—

Secondary

MeasureTime frame
Active Glucagon-like peptide-1 (GLP-1) concentration,Active Gastric inhibitory Polypeptide (GIP) concentration,Glucagon levels,Postprandial (1 and 2 hour) glucose levels,Fasting blood glucose levels,Insulin levels—

Countries

Japan

Contacts

Public ContactKensuke Ofuchi

Naka Kinen Clinic Clinical Laboratory

k-ofuchi@kensei-kai.com029-353-2800

Outcome results

None listed

Source: JPRN (via WHO ICTRP) · Data processed: Feb 4, 2026